Injection burden and treatment intervals of aflibercept in observe-and-plan regimen for neovascular age-related macular degeneration

IF 3 3区医学 Q1 OPHTHALMOLOGY

Acta Ophthalmologica Pub Date : 2024-05-11 DOI:10.1111/aos.16709

Yousif Subhi, Miklos Schneider, Javad Nouri Hajari, Morten la Cour

{"title":"Injection burden and treatment intervals of aflibercept in observe-and-plan regimen for neovascular age-related macular degeneration","authors":"Yousif Subhi, Miklos Schneider, Javad Nouri Hajari, Morten la Cour","doi":"10.1111/aos.16709","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>The Observe-and-Plan (O&P) regimen allows for individualised treatment. In this study, we evaluated injection burden and intervals using aflibercept in an O&P regimen for eyes with neovascular age-related macular degeneration (AMD).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This was a retrospective registry-based study of treatment-naïve eyes with neovascular AMD. Treatment data were compiled for 3 years after commencement of intravitreal aflibercept therapy. We evaluated clinical consequences at the first follow-up after loading dose, the proportion of patients who obtained and kept dry macula after loading dose, number of injections and intervals between injections.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Data were obtained for 1103 eyes. After loading dose, 0.4% were lost to follow-up, 7.5% discontinued, 50.9% booked for further injections and 41.3% booked for monthly observations. After loading dose, the macula remained dry in 49.2% at 3 months, 34.0% at 6 months, 23.7% at 12 months and 15.2% at 24 months. For the entire population, median cumulative total number of injections was 7, 12 and 15, after 1, 2 and 3 years, respectively. After the 3rd year, the proportion of eyes in the short 4–6 weeks treatment interval was 51.1%, 8 weeks interval was kept in 14.4% and the extended treatment intervals of 10 and 12 weeks was possible in 34.4%.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>After loading dose, one in two eyes required further injections. A large proportion required therapy with shorter intervals than the label-recommended 8 weeks. The large majority of those who obtained a dry macula after loading dose turned exudative again, mostly within the first 3 months.</p>\n </section>\n </div>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":"102 7","pages":"821-827"},"PeriodicalIF":3.0000,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Ophthalmologica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/aos.16709","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

The Observe-and-Plan (O&P) regimen allows for individualised treatment. In this study, we evaluated injection burden and intervals using aflibercept in an O&P regimen for eyes with neovascular age-related macular degeneration (AMD).

Methods

This was a retrospective registry-based study of treatment-naïve eyes with neovascular AMD. Treatment data were compiled for 3 years after commencement of intravitreal aflibercept therapy. We evaluated clinical consequences at the first follow-up after loading dose, the proportion of patients who obtained and kept dry macula after loading dose, number of injections and intervals between injections.

Results

Data were obtained for 1103 eyes. After loading dose, 0.4% were lost to follow-up, 7.5% discontinued, 50.9% booked for further injections and 41.3% booked for monthly observations. After loading dose, the macula remained dry in 49.2% at 3 months, 34.0% at 6 months, 23.7% at 12 months and 15.2% at 24 months. For the entire population, median cumulative total number of injections was 7, 12 and 15, after 1, 2 and 3 years, respectively. After the 3rd year, the proportion of eyes in the short 4–6 weeks treatment interval was 51.1%, 8 weeks interval was kept in 14.4% and the extended treatment intervals of 10 and 12 weeks was possible in 34.4%.

Conclusion

After loading dose, one in two eyes required further injections. A large proportion required therapy with shorter intervals than the label-recommended 8 weeks. The large majority of those who obtained a dry macula after loading dose turned exudative again, mostly within the first 3 months.

查看原文本刊更多论文

观察-计划方案中阿弗利百普治疗新生血管性老年黄斑变性的注射负担和治疗间隔。

目的：观察和计划（O&P）方案可实现个体化治疗。在这项研究中，我们评估了新生血管性老年性黄斑变性（AMD）患者在O&P方案中使用aflibercept的注射负担和间隔时间：这是一项以登记为基础的回顾性研究，研究对象是患有新生血管性黄斑变性的未接受过治疗的患者。我们收集了玻璃体内阿弗利百普治疗开始后3年的治疗数据。我们评估了负荷剂量后首次随访的临床后果、负荷剂量后获得并保持干燥黄斑的患者比例、注射次数和注射间隔：结果：共获得1103只眼睛的数据。结果：共获得 1103 只眼睛的数据，其中 0.4% 的患者在用药后失去了随访，7.5% 的患者中断了随访，50.9% 的患者预约了继续注射，41.3% 的患者预约了每月观察。用药后，49.2%的患者在 3 个月时黄斑仍然干燥，34.0%的患者在 6 个月时黄斑仍然干燥，23.7%的患者在 12 个月时黄斑仍然干燥，15.2%的患者在 24 个月时黄斑仍然干燥。整个人群在 1 年、2 年和 3 年后的累计注射次数中位数分别为 7 次、12 次和 15 次。第 3 年后，4-6 周短期治疗间隔的比例为 51.1%，8 周间隔的比例为 14.4%，10 周和 12 周延长治疗间隔的比例为 34.4%：结论：注射负荷剂量后，每两只眼睛中就有一只需要继续注射。结论：注射负荷剂量后，每两只眼睛中就有一只需要继续注射，其中很大一部分需要的治疗间隔比标签建议的 8 周更短。绝大多数在用药后黄斑干涩的患者在用药后 3 个月内再次出现渗出。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Ophthalmologica 医学-眼科学

CiteScore

7.60

自引率

5.90%

发文量

433

审稿时长

6 months

期刊介绍： Acta Ophthalmologica is published on behalf of the Acta Ophthalmologica Scandinavica Foundation and is the official scientific publication of the following societies: The Danish Ophthalmological Society, The Finnish Ophthalmological Society, The Icelandic Ophthalmological Society, The Norwegian Ophthalmological Society and The Swedish Ophthalmological Society, and also the European Association for Vision and Eye Research (EVER). Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses.